Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

DxS grants molecular diagnostic technology licence to DiagnoCure

DxS : 11 September, 2007  (New Product)
DxS has granted a licence to DiagnoCure of Canada, for DxS's Scorpions molecular diagnostic technology.
The agreement enables DiagnoCure to gain access to Scorpions for the development of their GCC based molecular test for colorectal cancer.

Dr Timothy J Holzer, vice president of R&D of DiagnoCure said of the agreement 'The Scorpions molecular diagnostic technology has the potential to significantly improve productivity and lower cost with regard to the processing of our gene-based tests. Most importantly, we intend to make use of it in our new GC-C tests for colorectal cancer.'

The DiagnoCure test uses Scorpions to detect GC-C (guanylyl cyclase c), a gene that appears normally in cells lining the intestinal tract, but is found on the outside of the intestine when colorectal cancer has metastasized.

DxS's Scorpions technology is ideally suited for cancer in vitro diagnostics, the probes are highly sensitive, sequence-specific, bi-functional molecules containing a PCR primer covalently linked to a probe. Scorpion probes provide strong fluorescent signals, excellent sequence discrimination, short reaction times, and predictable probe design.

The interaction of the probe and the desired target occurs very rapidly and in advance of any competing side reactions such as the formation of internal secondary structures or re-annealing. The intra-molecular nature of the Scorpions reaction means that it is ideally suited for fast, quantitative, real-time PCR analysis.

Commenting on the agreement, Dr Stephen Little, chief executive officer for DxS, said, 'We are delighted to have finalised our Scorpions license arrangement with DiagnoCure. It is a confirmation of confidence in our unique molecular technology, by a recognised leader in the field of cancer diagnostics.'
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo